Pulmonary hypertension pediatric research and clinical trials

LIke ThisLIke ThisLIke ThisLIke ThisLIke This

Contact the Pulmonary Hypertension Program

Boston Children’s Hospital is home to the world’s most extensive research enterprise at a pediatric hospital. We also have many partnerships with the top research, biotech and health care organizations, and we work together to find innovative ways to improve kids’ health.

Thanks to advances in basic science and clinical research, better therapies for pulmonary hypertension are being developed every year.

  • We are a leader in the use of nitric oxide, prostacyclin analogs, endothelin antagonists and other investigational therapies to treat both idiopathic and secondary pulmonary hypertension in children.
  • Researchers and doctors have conducted a quality of life study for patients with pulmonary hypertension in an effort to identify strategies to improve development.

Current therapeutic trials include:

  • evaluation of a new, more efficient way of delivering inhaled nitric oxide
  • study of the long-term effects of ambrisentan. Used to treat PH, this medicine can help make exercise and breathing easier.
We are grateful to have been ranked #1 on U.S. News & World Report's list of the best children's hospitals in the nation for the third year in a row, an honor we could not have achieved without the patients and families who inspire us to do our very best for them. Thanks to you, Boston Children's is a place where we can write the greatest children's stories ever told.”
- Sandra L. Fenwick, President and CEO

Boston Children's Hospital 300 Longwood Avenue, Boston, MA 02115 617-355-6000 | 800-355-7944

Close